[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599933":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":54,"collaborators":26,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":26,"eligibilityCriteria":62,"healthyVolunteers":59,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":26,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Khyber Teaching Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention group","EXPERIMENTAL","group A (intervention group) will receive 5 ml of 0.5% bupivacaine infiltrated at each port site",[13],"Drug: 5 ml of 0.5% bupivacaine infiltrated at each port site",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","PLACEBO_COMPARATOR","Group B (intervention group) will receive 5 ml of 0.9% Normal Saline infiltrated at each port site",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","5 ml of 0.5% bupivacaine infiltrated at each port site","5 ml of 0.5% bupivacaine infiltrated at each port site after the arthroscopic procedures",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","5ml 0.9%normal saline infiltrated at port site",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Zeeshan Arif","CONTACT","+923475772757","zeeshanarif0061@gmail.com",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":26,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Khyber teaching Hospital Peshawer","RECRUITING","Peshawar","KPK","Pakistan","PK",{"type":46,"coordinates":47},"Point",[48,49],71.57849,34.008,{"lat":49,"lon":48},[52],{"name":33,"role":34,"phone":53,"phoneExt":26,"email":36},"03475772757",{"type":55,"investigatorFullName":33,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Trainee Medical Officer","100599933","phase-4-effectiveness-of-per-operative-bupivicaine-in-reducing-postoperative-pain-at-port-site-and-improving-mobility-in-knee-arthoscopic-procedures-100599933",false,"NCT07090928","Effectiveness of Per-Operative Bupivicaine in Reducing Postoperative Pain at Port Site and Improving Mobility in Knee Arthoscopic Procedures","Inclusion Criteria Either Male or Female Age range: 18-70 Years Patients scheduled to undergo elective knee arthroscopic procedures Able to understand the VAS pain scale Exclusion Criteria Either Male or Female Age range: 18-70 Years Patients scheduled to undergo elective knee arthroscopic procedures Able to understand the VAS pain scale Known hypersensitivity or allergy to bupivacaine or any local anesthetics Chronic pain conditions requiring regular pain medications History of drug abuse (mainly to opioids) Pregnant women Pre-existing impaired knee mobility No willing to participate in trial","ALL","18 Years","70 Years",{"count":67,"type":68},60,"ESTIMATED","INTERVENTIONAL",[71],"PHASE4","The investigator's aim is to evaluate the effectiveness of per-operative bupivacaine infiltration at arthroscopic port sites in reducing post-operative pain compared to placebo in patients undergoing knee arthroscopic procedures.",[74],"Arthroscopic Surgery",[76,77,78,79,80,81,82,83,84],"Bupivacaine","Postoperative Pain","Port Site Pain","Arthroscopy","Mobility Improvement","Local Anesthetic","Perioperative Analgesia","Minimally Invasive Surgery","Randomized Controlled Trial","2026-06-20",{"date":87,"type":88},"2026-06-25","ACTUAL",{"date":90,"type":88},"2026-03-10",{"date":92,"type":68},"2026-06",{"name":5,"class":6},1]